Abstract
Myeloid leukaemia cells are sensitive to attack by elements of the immune system as evidenced by the effects of T cell depletion, graft versus leukaemia and donor lymphocyte infusion on leukaemic recurrence. An implication is that the immune system can be manipulated to enhance anti-leukaemic effects by exogenous stimulation including the use of immunostimulatory cytokines. These could potentially be used in a controlled manner that avoids the clinical problems associated with graft-versus-host disease. The cytokine used most extensively to date is interleukin-2 (IL2), a molecule that induces T lymphocyte proliferation and the generation of MHC unrestricted cytotoxicity. Despite over 10 years of clinical experience, the data on efficacy in acute myeloid leukaemia remains unclear due to lack of adequate randomised trials. IL2 appears to be effective in patients with low level marrow infiltration by acute myeloid leukaemia (AML) blast cells. It is less effective when patients present or relapse with packed bone marrows. The logical assumption that IL2 treatment given during states of minimal residual disease will reduce the incidence or speed of disease recurrence remains to be adequately tested. IL2 administration is associated with characteristic clinical adverse effects and with specific immuno-haematological changes. The use of other cytokines for immune manipulation in patients with AML is so far essentially limited to the research laboratory. Potential uses include cytokine induced blast differentiation to dendritic cells and the use of irradiated cytokine gene transduced leukaemic cells as vaccines.
Keywords: human acute leukaemia, cytotoxicity
Current Pharmaceutical Design
Title: Cytokine Manipulation of the Immune Response in the Treatment of Human Acute Leukaemia
Volume: 8 Issue: 5
Author(s): David Gottlieb
Affiliation:
Keywords: human acute leukaemia, cytotoxicity
Abstract: Myeloid leukaemia cells are sensitive to attack by elements of the immune system as evidenced by the effects of T cell depletion, graft versus leukaemia and donor lymphocyte infusion on leukaemic recurrence. An implication is that the immune system can be manipulated to enhance anti-leukaemic effects by exogenous stimulation including the use of immunostimulatory cytokines. These could potentially be used in a controlled manner that avoids the clinical problems associated with graft-versus-host disease. The cytokine used most extensively to date is interleukin-2 (IL2), a molecule that induces T lymphocyte proliferation and the generation of MHC unrestricted cytotoxicity. Despite over 10 years of clinical experience, the data on efficacy in acute myeloid leukaemia remains unclear due to lack of adequate randomised trials. IL2 appears to be effective in patients with low level marrow infiltration by acute myeloid leukaemia (AML) blast cells. It is less effective when patients present or relapse with packed bone marrows. The logical assumption that IL2 treatment given during states of minimal residual disease will reduce the incidence or speed of disease recurrence remains to be adequately tested. IL2 administration is associated with characteristic clinical adverse effects and with specific immuno-haematological changes. The use of other cytokines for immune manipulation in patients with AML is so far essentially limited to the research laboratory. Potential uses include cytokine induced blast differentiation to dendritic cells and the use of irradiated cytokine gene transduced leukaemic cells as vaccines.
Export Options
About this article
Cite this article as:
Gottlieb David, Cytokine Manipulation of the Immune Response in the Treatment of Human Acute Leukaemia, Current Pharmaceutical Design 2002; 8 (5) . https://dx.doi.org/10.2174/1381612023396087
DOI https://dx.doi.org/10.2174/1381612023396087 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Biology of Protooncogene c-kit Receptor and Spermatogenesis
Current Pharmacogenomics PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Current Pharmaceutical Design Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis
Current Signal Transduction Therapy Making Sense of Molecular Signatures in The Immune System
Combinatorial Chemistry & High Throughput Screening Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry Therapeutic Potential of HDAC Inhibitors in the Treatment of Cardiac Diseases: A Short Review
Current Drug Targets Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors
Current Pharmaceutical Design Treatment of Relapsed Acute Myeloid Leukaemia
Reviews on Recent Clinical Trials Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines
Current Medicinal Chemistry New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine Patents in Cancer Stem Cells
Recent Patents on Biomarkers Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Advances in Stem Cell Therapy for Leukemia
Current Stem Cell Research & Therapy Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy
Current Pharmacogenomics Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry